Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IS Pharma launches drug for bleeding oesophageal varices in the UK

This article was originally published in Scrip

Executive Summary

IS Pharma has launched Variquel (terlipressin) for the treatment of bleeding oesophageal varices in the UK. The synthetic vasopressin analogue, which gained approval under the EU's mutual recognition procedure in March this year, is already marketed for this indication in Germany, Austria and Switzerland. Five vials of the product, for five injections, will cost £89.48. Terlipressin is under regulatory review, as Orphan Therapeutic's Lucassin, in the US as a treatment for type 1 hepatorenal syndrome (scripnews.com, June 16th, 2009).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC002862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel